• News & Events
  • Contact
  • Home
  • Company
    • History and Mission
    • Team
    • Careers
  • Research
    • Technology
    • Products
  • Clinical trials
  • For patients
  • Partnering
  • News & Events
  • Contact
Human SARS-CoV-2 neutralizing antibody COR-101 demonstrates high efficacy in a COVID-19 animal model and is ready to be used in clinical studies to treat COVID-19 patients

Human SARS-CoV-2 neutralizing antibody COR-101 demonstrates high efficacy in a COVID-19 animal model and is ready to be used in clinical studies to treat COVID-19 patients

by wohlenberg@vierviertel.com | Dec 18, 2020 | 2020, News

COR-101 decreased SARS-CoV-2 virus load in the lung by more than 99%COR-101 induced recovery after 2 days, compared to 7 days untreated CORAT Therapeutics GmbH today reports the successful conclusion of hamster disease model tests of their lead candidate COR-101...
How human antibody COR-101 neutralizes the coronavirus SARS-CoV-2

How human antibody COR-101 neutralizes the coronavirus SARS-CoV-2

by wohlenberg@vierviertel.com | Dec 4, 2020 | 2020, News

Because SARS-CoV-2 is a novel virus, many people have not yet developed antibodies against the pathogen. Vaccines can protect healthy people, but they cannot cure people affected by COVID-19. Furthermore, not everyone responds to the vaccine. Passive immunisation by...
CORAT won the Durchstarter Award of the State of Lower Saxony

CORAT won the Durchstarter Award of the State of Lower Saxony

by wohlenberg@vierviertel.com | Dec 2, 2020 | 2020, News

Durchstarterpreis award ceremony “And the winner is: CORAT Therapeutics!” The online award ceremony with the Nominees (top) and Stefan Muhle, Dr. Althusmann and Dr. Sabine Johannsen (left to right). (Photos: NBank) In an event with Economics Minister Dr....
CORAT lead product COR-101 ready for clinical trials

CORAT lead product COR-101 ready for clinical trials

by wohlenberg@vierviertel.com | Nov 15, 2020 | 2020, News

15.11.2020 – CORAT Therapeutics CEO Dr. Andreas Herrmann today proudly reports the conclusion of the production campaign providing the first larger batch of COR-101 ready for the patients. COR-101 is a fully human antibody developed in Braunschweig which...
CORAT won the Innovation Award of the State of Lower Saxony

CORAT won the Innovation Award of the State of Lower Saxony

by wohlenberg@vierviertel.com | Sep 28, 2020 | 2020, News

Lower Saxony’s Minister of Economics Dr. Bernd Althusmann and Lower Saxony’s Minister of Science Björn Thümler, together with Prof. Josef von Helden, Chairman of the Board of the Innovation Network Lower Saxony, once again honoured visionary ideas,...
https://corat-therapeutics.com/wp-content/uploads/2021/10/Antibodies-fight_Coronavirus_NewColors_v03.mp4

Fighting SARS-CoV-2 with antibodies

by wohlenberg@vierviertel.com | Sep 13, 2020 | 2020, News

CORAT SAB member Prof. Dr. Dübel explains how antibodies protect our body against coronavirus infections.
« Older Entries

Recent Posts

  • € 38.7 Mio. German government funding for the clinical development of a Corona medication
  • CORAT Therapeutics GmbH announces partnership with Dermapharm Holding SE
  • CORAT antibody COR-101 binds and inhibits all B.1.617 SARS-CoV-2 variants, including the fast proliferating “delta” variant
  • CORAT Therapeutics secures additional funding for Phase II clinical evaluation of its COVID-19 treatment
  • TV report on COR-101

Recent Comments

No comments to show.

Contact

Contact Us

Contact

CORAT Therapeutics GmbH
Inhoffenstr. 7
38124 Braunschweig
Germany

Phone +49 1522 4047488
Write an e-mail

Commercial Registry

HRB 208500
Registergericht Braunschweig

V.i.S.d.P.: Dr. Andreas Herrmann

Pages

Home
Company
History and Mission
Careers
Team
Research
Clinical trails
Partnering
News & Events

Social

Twitter

Legal

Imprint
Privacy Statement
Cookie Policy

© Copyright 2021 – CORAT Therapeutics GmbH